Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon to Raise Nearly $40M Financing

NEW YORK (GenomeWeb News) - Lexicon Genetics today said it has entered into agreements with unspecified investors to purchase up to 10,582,011 shares of its stock.
 
The Woodlands, Texas-based biopharmaceutical company said "select institutional investors" agreed to purchase the stock at a price of $3.78 per share, and that it expects net proceeds of up to $37.5 million.
 
The agents for the placement were Banc of America Securities and Lazard Capital Markets.
 
Lexicon studies gene function and behavior to help in the development of
small molecule, antibody, and protein drugs.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.